Lenvatinib Yields Survival Benefit, Manageable Toxicities in Recurrent HCC After Liver Transplantation

Article

Patients with recurrent hepatocellular carcinoma after liver transplantation were treated with lenvatinib and saw promising efficacy.

Results from the REFLECT trial (NCT01761266) showed a survival benefit and managable toxicity was seen when patients with lenvatinib (Lenvima) for recurrent hepatocellular carcinoma (HCC) after liver transplantation, according to a presentation from the 2022 Gastrointestinal Cancers Symposium.

“Despite of immunotherapeutic advances (atezolizumab [Tecentriq] plus bevacizumab, pembrolizumab [Keyruda] and nivolumab [Opdivo]) in the management of advanced HCC, patients with prior [liver transplantation] are not benefitted because of the risk of allograft rejection, and they are also excluded in most prospective clinical trials for novel agents,” Kyunghye Bang, MD, of the Department of Oncology at Asan Medical Center at the University of Uslan College of Medicine in Seoul, Korea, said during the presentation.

In this study, researchers assessed the impact of lenvatinib in 22 patients with recurrent HCC after liver transplantation who were treated in a medical center in South Korea between November 2019 and March 2021. Patients who weighed 60 kg or more received 12 mg of lenvatinib per day, whereas those who weighed less than 60 mg received 8 mg of the drug per day. Response to lenvatinib and adverse events associated with the treatment were graded by RECIST v1.1 and NCI CTCAE v5.0.

Patients in the study had a median age of 58 years (range, 20-69) and 95.5% (n = 21) were men. The most common HCC etiology was hepatitis B (n = 18; 81.8%). Recurrence after liver transplantation occurred at a median of 6.6 months (95% CI, 4.2-9.1 months). Before treatment with systemic therapy, the most commonly used therapy for recurrent HCC after a liver transplant was transarterial embolization (n = 12; 54.5%).

Most patients at the time of lenvatinib initiation were Child-Pugh A (n = 21; 95.5%), with 15 patients (68.2%) classified as ALBI grade 1 and 7 patients (31.8%) classified as ALBI grade 2. All patients in this study were at BCLC stage C. In addition, lenvatinib was administered as either a first-line (n = 19) or second-line therapy (n = 3).

Lenvatinib demonstrated an objective response rate of 13.6%. The median progression-free survival (PFS) was 6.6 months (95% CI, 3.6-9.5 months) during a median follow-up of 5.2 months (range, 1.7-14.5 months). Also during follow-up, overall survival (OS) was 14.5 months (95% CI, not assessable). The 6-month OS rate was 88.8%, and the 6-month PFS rate was 59.8%.

ALBI grade may be a predictor of OS, as patients with ALBI grade 2 had significantly poorer OS (11.1 months; 95% CI, not accessible) compared with those with ALBI grade 1 (14.5 months; 95% CI, not accessible; P = .011). Adverse events that occurred with lenvatinib treatment included thrombocytopenia (n = 7; 31.8%), hypertension (n = 8; 36.4%) and fatigue (n = 6; 27.3%).

Reference:

Bang K, Yoo C, Ryu M-H, et al. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation: A retrospective analysis. Presented at: 2022 ASCO Gastrointestinal Cancers Symposium; January 20-22, 2022; Virtual. Abstract

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content